ストックスクリーナーアプリを入手
13.00
4.22%
0.54
前日終値:
$12.46
開ける：
$12.38
24時間の取引高:
409.25K
Relative Volume:
0.38
時価総額：
$1.62B
収益：
$1.12B
当期純損益:
$5.00M
株価収益率:
1,300.00
EPS:
0.01
ネットキャッシュフロー:
$-383.00M
1週間 パフォーマンス:
+9.82%
1か月 パフォーマンス:
+8.39%
6か月 パフォーマンス:
+15.94%
1年 パフォーマンス:
-29.27%
1日の値動き範囲:
$12.36
$13.00
1週間の範囲:
$11.83
$13.00
52週間の値動き範囲:
$7.33
$18.50
Indivior Plc Stock (INDV) Company Profile
INDV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
12.99 | 1.48B | 1.12B | 5.00M | -383.00M | 0.01 |
|
HLN
Haleon Plc Adr
|
11.12 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.67 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.95 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.20 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
Indivior Plc (INDV) 最新ニュース
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Trending tickers: The latest investor updates on Tesla, Palantir, Sanofi, Babcock and Indivior - Yahoo
Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape - Kalkine Media
Indivior to delist from London Stock Exchangewill stay on Nasdaq - Insider Media Ltd
Drug maker Indivior joins London Stock Exchange exodus, 2 Jun 2025 11:00 - Shares Magazine
Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing - Kalkine Media
Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq - Kalkine Media
FTSE pharma giant joins London stock market exodus - The Telegraph
Indivior (INDV) Delists from London to Focus on U.S. Market - GuruFocus
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq - MSN
Indivior brings curtain down on turbulent 11-year run in London - Proactive financial news
Indivior drops London listing to focus on U.S. market By Investing.com - Investing.com Nigeria
Indivior To Delist From LSE To Better Align With US Focused Business - Nasdaq
Indivior to cancel secondary listing in London - Sharecast.com
Indivior Plans to Cancel London Listing After Moving Primary to US - Bloomberg
Drug maker Indivior to abandon London stock market for the US - Yahoo
Indivior to Cancel London Stock Exchange Listing, Focuses on Nasdaq - TipRanks
Indivior to Cancel Secondary Listing on London Stock Exchange, Maintains Primary Nasdaq Listing | Indivior Stock News - paginasiete.bo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing - marketscreener.com
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News - GuruFocus
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - Bluefield Daily Telegraph
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC LawsuitINDV - ACCESS Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer - The Malaysian Reserve
Indivior appoints Patrick Barry as Chief Commercial Officer By Investing.com - Investing.com South Africa
Indivior Announces Patrick Barry as Chief Commercial Officer | I - GuruFocus
Indivior Announces Patrick Barry as Chief Commercial Officer | INDV Stock News - GuruFocus
Indivior Taps Former Endo Executive to Drive SUBLOCADE Growth Strategy - Stock Titan
Indivior PLC (INDV) Stock Analysis: A 30% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Investors in Indivior (LON:INDV) have seen solid returns of 156% over the past five years - Yahoo Finance
How To Trade (INDV) - news.stocktradersdaily.com
Indivior PLC (LON:INDV) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
Naloxone Market Projected To Witness Massive Growth, 2025-2032 - openPR.com
Court of Appeal upholds representative action strike out in Wirral Council v Indivior/Reckitt, but claimant applies for permission to appeal to Supreme Court - stewartslaw.com
Indivior PLC Aligns CEO Compensation with Long-Term Performance Goals - TipRanks
Indivior to Participate in Upcoming Investor Events - StreetInsider
Indivior to Participate in Upcoming Investor Events | INDV Stock News - GuruFocus
Indivior announces participation in investor conferences By Investing.com - Investing.com India
Indivior to Engage with Investors at Key Healthcare Conferences - TipRanks
Indivior to Participate in Upcoming Investor Events – Company Announcement - Financial Times
Drug Addiction Treatment Market Projected To Witness Massive - openPR.com
(INDV) Long Term Investment Analysis - news.stocktradersdaily.com
Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com
Indivior advances GABA-B PAM program for substance use disorders through IND-enabling studies - BioWorld MedTech
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - Yahoo
Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your RightsINDV - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Indivior PLC (INDV) - ACCESS Newswire
Indivior PLC Announces AGM Results with Key Resolutions Passed - TipRanks
Indivior PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationINDV - ACCESS Newswire
Indivior PLC Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights – INDV - ACCESS Newswire
Indivior Plc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
3.28%
2.99%
大文字化:
|
ボリューム (24 時間):